Day One Biopharmaceuticals, Inc.DAWNEarnings & Financial Report
Nasdaq
NextMar 25, 2026
DAWN Q3 2025 Key Financial Metrics
Revenue
$39.8M
Gross Profit
N/A
Operating Profit
$-24.3M
Net Profit
$-19.7M
Gross Margin
N/A
Operating Margin
-60.9%
Net Margin
-49.6%
YoY Growth
-57.6%
EPS
$-0.19
Financial Flow
Day One Biopharmaceuticals, Inc. Q3 2025 Financial Summary
Day One Biopharmaceuticals, Inc. reported revenue of $39.8M for Q3 2025, with a net profit of $-19.7M (-49.6% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $39.8M |
|---|---|
| Net Profit | $-19.7M |
| Gross Margin | N/A |
| Operating Margin | -60.9% |
| Report Period | Q3 2025 |
Day One Biopharmaceuticals, Inc. Annual Revenue by Year
Day One Biopharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $131.2M).
| Year | Annual Revenue |
|---|---|
| 2024 | $131.2M |
| 2022 | $4.7M |
Income Statement
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $8.2M | $93.8M | $29.2M | $30.8M | $33.9M | $39.8M |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | 313.9% | -57.6% |
Balance Sheet
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $414.2M | $326.6M | $400.4M | $600.8M | $582.8M | $534.4M | $519.0M | $513.8M |
| Liabilities | $24.6M | $29.8M | $93.7M | $45.3M | $80.0M | $54.8M | $58.2M | $62.9M |
| Equity | $389.6M | $296.8M | $306.7M | $555.5M | $502.8M | $479.5M | $460.8M | $450.9M |
Cash Flow
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-37.1M | $-49.7M | $-49.1M | $50.8M | $-30.0M | $-59.0M | $-24.8M | $-5.8M |